Top 10 Information Technology Companies To Watch In Right Now

EMC (EMC)�� stock was flat over the course of 2013.� In fact, the stock has been flat over the past three years ��sigificantly underperforming the near 50% gain in the S&P 500 Index.� The stock has been buffetted over fears that the Company�� current decelerated growth is in secular decline due to a number of competitive threats.� The first threat is that flash storage and software-defined storage will cannibalize traditional hard disk drives.� Two, the public cloud is only a threat (and not an opportunity) that disintermediates information technology (IT) spend from both EMC and VMware (EMC maintains an over 80% ownership stake in VMW).� Third, VMware�� entrenched vSphere gets displaced by Open-Source and Microsoft�� Hyper-V.� Fourth, recent premium-priced acquisitions of Data Domain and Isilon are evidence of lack of internal product development.

EMC�� products ��both hardware and software - are litearlly a geek�� wonderland alphabet soup, which include Storage Area Network (SAN), Network Attached Storage (NAS), Direct Attached Storage (DAS), Virtual SAN, All-Flash XtremIO, Atmos, Avamar, �Data Domain, Isilon, Pivotal, ViPR Software Defined Storgae, VMAX, VNX, VNXe, VPLEX, VSPEX (none of these are typos).� Information storage makes up 70% of revenues and virtualization 23% of revenues.� Products generate 55% of revenues.� Services generate 45% of revenues.� The Company�� gross profit split is approximaltey 67% data storage and 31% virtualization.

Hot Life Sciences Companies To Buy For 2015: Array BioPharma Inc.(ARRY)

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases in North America, Europe, and the Asia Pacific. Its programs under development include ARRY-520, a kinesin spindle protein inhibitor in Phase 2 clinical trial for patients with multiple myeloma; ARRY-614, a p38/Tie-2 dual inhibitor in Phase 1 clinical trial for patients with myelodysplastic syndrome; ARRY-380, a HER2 inhibitor in Phase 1 clinical trial for breast cancer; ARRY-797, a p38 inhibitor in Phase 2 clinical trial for pain; and ARRY-502, a CRTh2 antagonist in Phase 1 clinical trial for allergic inflammation. The company?s partnered drugs in clinical development comprise Selumetinib and AZD8330 MEK inhibitors for cancer in Phase 2 trial; MEK162 and MEK300 MEK inhibitors for cancer in Phase 2 trial; Danoprevir, a Hepatitis C virus protease inhibitor in Phase 2 trial; ARRY-543, a HER2/EGFR inhibitor in Phase 2 trial for solid tumors; and LY2603618, a ChK-1 inhibitor in Phase 2 trial for cancer. Its partnered drugs in clinical development also include AMG 151, a glucokinase activator in Phase 1b trial for Type 2 diabetes; GDC-0068, a AKT inhibitor in Phase 1b trial for cancer; VTX-2337, a toll-like receptor in Phase 1b trial for cancer; VTX-1463, a toll-like receptor in Phase 1b trial for allergy; ARRY-382, a cFMS inhibitor in Phase 1 trial for cancer; and ARRY-575 and GDC-0425, which are ChK-1 inhibitors in Phase 1 trial for cancer. The company has collaborations with Amgen, Inc.; ASLAN Pharmaceuticals Pte Ltd.; AstraZeneca, PLC; Celgene Corporation; Genentech, Inc.; Novartis International Pharmaceutical Ltd.; InterMune, Inc.; Eli Lilly and Company; and VentiRx Pharmaceuticals, Inc for the development and commercialization of the partnered drugs. Array BioPharma Inc. was founded in 1998 and is headquartered in Boulder, Colorado.

Advisors' Opinion:

• [By Sean Williams]

  What: Shares of Array BioPharma (NASDAQ: ARRY  ) , a biopharmaceutical company focused on the development of small molecule drugs for the treatment of cancer and inflammatory diseases, soared as much as 29% after the company reported positive phase 2 data on ARRY-502, an experimental drug designed to treat mild to moderate persistent allergic asthma.

• [By Sean Williams]

  Array BioPharma (NASDAQ: ARRY  ) presented some particularly intriguing findings with its MEK inhibitor, selumetinib, which it has licensed out to AstraZeneca�to treat uveal melanoma (cancer of the eye). Historically this is a very difficult to treat disease, but initial studies of selumetinib more than doubled the time it took for the disease to progress compared to the current standard of treatment, temozolomide. In trials, selumetinib delivered 15.9 weeks without disease progression, an overall response rate of 50%, and major tumor shrinkage exhibited in 15% of patients. For temozolomide, steady disease was only established for a median of seven weeks with no tumor shrinkage present.�

Top 10 Information Technology Companies To Watch In Right Now: Alliant Energy Corporation (LNT)

Alliant Energy Corporation operates in electric and gas utility businesses in the United States. The company, through its subsidiary, Interstate Power and Light Company, engages in the generation and distribution of electric energy; and the distribution and transportation of natural gas in Iowa and southern Minnesota. As of December 31, 2009, it supplied electric and gas service to approximately 525,334 and 233,841 retail customers. Alliant Energy Corporation also provides steam services, and various other energy-related products and services to customers in Iowa. The company, through its other subsidiary, Wisconsin Power and Light Company (WPL), involves in the generation and distribution of electric energy; and the distribution and transportation of natural gas primarily in south and central Wisconsin markets. As of December 31, 2009, WPL supplied electric and gas service to 453,573 and 177,968 retail customers. In addition, Alliant Energy Corporation has investments in environmental consulting, and engineering and renewable energy services businesses. It also engages in transportation business, which includes a short-line railway for the provision of freight services between Cedar Rapids and Iowa City in Iowa; barge terminal and hauling services on the Mississippi River; and other transfer and storage services. The company was founded in 1917 and is based in Madison, Wisconsin.

Advisors' Opinion:

• [By Seth Jayson]

  Alliant Energy (NYSE: LNT  ) is expected to report Q1 earnings on May 3. Here's what Wall Street wants to see:

  The 10-second takeaway
  Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Alliant Energy's revenues will contract 0.0% and EPS will grow 24.0%.

• [By David Dittman]

  Question: What�� your outlook for Alliant Energy Corp (NYSE: LNT)?

  Answer: I rate Alliant Energy a buy under 57. It’s pushed out a little beyond that right now.

• [By Eric Volkman]

  Alliant Energy (NYSE: LNT  ) is staying true to form and pumping out its usual reward for shareholders. The company has announced it will distribute a dividend of $0.47 per share of its common stock on May 15 to shareholders of record as of April 30. This matches the firm's previous distribution, which was dispensed at the end of January. Previous to that, Alliant had paid $0.45 per share.

• [By Eric Volkman]

  The lights of Alliant Energy (NYSE: LNT  ) are continuing to burn brightly, at least as far as the utility operator's shareholder payouts are concerned. The company has declared a quarterly common stock dividend of $0.47 per share, to be paid on Aug. 15 to holders of record as of July 31. That amount matches both of the firm's previous two disbursements, the most recent of which was paid in May. Before that, Alliant Energy handed out 2 cents less at $0.45 per share.

Top 10 Information Technology Companies To Watch In Right Now: Alnylam Pharmaceuticals Inc.(ALNY)

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its core product programs under clinical or pre-clinical development include ALN-TTR, a Phase I clinical trial program for the treatment of transthyretin-mediated amyloidosis; ALN-APC, a Phase I clinical trial program for the treatment of hemophilia; ALN-PCS for the treatment of severe hypercholesterolemia; ALN-HPN, a pre-clinical development for the treatment of refractory anemia; and ALN-TMP, a pre-clinical development for the treatment of hemoglobinopathies, including beta-thalassemia and sickle cell anemia. The company?s partner-based programs comprise ALN-RSV01, a Phase II clinical trial program for the treatment of respiratory syncytial virus infection; ALN-VSP, a Phase I clinical trial completed program for the treatment of liver cancers; and ALN-HTT, a pre-clinical development for the treatment of Huntington?s disease. It has strategic alliances with Novartis Pharma AG; F. Hoffmann-La Roche Ltd; Takeda Pharmaceutical Company Limited; Isis Pharmaceuticals, Inc.; Medtronic Inc.; Kyowa Hakko Kirin Co., Ltd.; and Cubist Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Advisors' Opinion:

• [By Garrett Cook]

  Alnylam Pharmaceuticals (NASDAQ: ALNY) shares were also up, gaining 20.89 percent to $88.07 after the company reported six-month clinical data from patisiran phase 2 OLE study in patients with familial amyloidotic polyneuropathy.

• [By Keith Speights]

  Good news comes in threes
  Alnylam Pharmaceuticals (NASDAQ: ALNY  ) had a triple-whammy of good news this week. Shares shot up by 22% as a result.

Top 10 Information Technology Companies To Watch In Right Now: ANSYS Inc (ANSS)

ANSYS, Inc. (ANSYS) develops and globally markets engineering simulation software and services used by engineers, designers, researchers and students across a range of industries and academia, including aerospace, automotive, manufacturing, electronics, biomedical, energy and defense. The Company distributes its ANSYS suite of simulation technologies through a global network of independent resellers and distributors (collectively, channel partners) and direct sales offices in global locations. The Company�� product portfolio consists of ANSYS Workbench, multiphysics product, structural mechanics, fluid dynamics, explicit dynamics, electromagnetic, system simulation, simulation process and data management, academic, high-performance computing (HPC), geometry interfaces, meshing and Apache design low-power electronic solutions. On August 1, 2011, the Company acquired Apache Design, Inc.

ANSYS Workbench

ANSYS Workbench is the framework upon which the Company�� suite of advanced engineering simulation technologies is built. The ANSYS Workbench platform delivers productivity, enabling Simulation Driven Product Development.

Multiphysics

The Company�� multiphysics product suite allows engineers and designers to create virtual prototypes of their designs operating under multiphysics conditions. ANSYS multiphysics software enables engineers and scientists to simulate the interactions between structural mechanics, heat transfer, fluid flow and electromagnetics all within a single, engineering simulation environment.

Structural Mechanics

The Company�� structural mechanics product suite offers simulation tools for product design. These tools have capabilities that cover a range of analysis types, elements, contacts, materials, equation solvers and coupled physics capabilities all focused towards understanding and solving complex design problems.

Fluid Dynamics

The Company�� fluid dynamics product suit! e offers modeling of fluid flow and other related physical phenomena. Fluid flow analysis capabilities provide all the tools needed to design new fluids equipment and to troubleshoot already existing installations. The fluid dynamics product suite contains general-purpose computational fluid dynamics software and specialized products to address specific industry applications.

Explicit Dynamics

The Company�� explicit dynamics product suite simulates events involving short-duration, large-strain, large-deformation, fracture, complete material failure or structural problems with complex interactions. This product suite is used for simulating physical events that occur in a short period of time and may result in material damage or failure.

Electromagnetics

The Company�� electromagnetics product suite provides field simulation software for designing high-performance electronic and electromechanical products. The software streamlines the design process and predicts performance - all prior to building a prototype - of mobile communication and Internet-access devices, broadband networking components and systems, integrated circuits (IC) and printed circuit boards (PCB), as well as electromechanical systems such as automotive components and power electronics equipment.

System Simulation

The Company delivers the ability to perform complete simulation studies as a system for some of the product designs. This is accomplished through a complete set of physics solutions that are integrated into a multiphysics capabilities set. A collaborative simulation environment provides modeling scalability for evaluating entire systems, including three dimensional (3-D) high-fidelity models, multibody dynamics, circuit reduced-order models, and any combination of these.

Simulation Process and Data Management

ANSYS Engineering Knowledge Manager (ANSYS EKM) is a solution for simulation-based process and data management. ANSY! S EKM pro! vides solutions to all levels of a company, enabling an organization to address the issues associated with simulation data, including backup and archival, traceability and audit trail, process automation and intellectual property protection.

Academic

The Company�� academic product suite provides a portfolio of academic products based on several usage tiers: associate, research and teaching. Each tier includes various noncommercial products that bundle a range of physics and advanced coupled field solver capabilities. The academic product suite provides entry-level tools intended for class demonstrations and hands-on instruction. It provides flexible terms of use and more complex analysis suitable for doctoral and post-doctoral research projects. The Company also provides a product suitable for student use at home.

High-Performance Computing

The Company�� HPC product suite enables insight into product performance. The HPC product suite delivers cross-physics parallel processing capabilities for the full spectrum of the Company�� simulation software by supporting structural, fluids, thermal and electromagnetic simulations in a single HPC solution.

Geometry Interfaces

The Company offers geometry handling solutions for engineering simulation in an integrated environment with direct interfaces to all CAD systems, support of additional readers and translators. It also offers an integrated geometry modeler focused on analysis.

Meshing

Creating a mesh that transforms a physical model into a mathematical model is a critical and foundational step in almost every engineering simulation study. The Company�� meshing technology provides a means to balance these requirements, obtaining the right mesh for each simulation in the most automated way possible.

Apache Design Low-Power Electronic Solutions

The Company�� suite of Apache software delivers power analysis and optimization pl! atforms a! long with integrated methodologies that provide capabilities for managing the power budget, power delivery integrity, and power-induced noise in an electronic design, from initial prototyping to system sign-off. These solutions deliver correlation to silicon measurement, and the capacity to handle an entire electronic system, including IC, package, and PCB.

Advisors' Opinion:

• [By Jonas Elmerraji]

  We're seeing the exact same setup in shares of simulation software maker ANSYS (ANSS). Like CSC, ANSYS is sandwiched between a horizontal price ceiling above shares around $90 a share and a similar horizontal floor at $83.50 a share. From here, the trading signal comes on a breakout outside of the channel.

  Whenever you're looking at any technical price pattern, it's critical to think in terms of those buyers and sellers. Rectangles, triangles, and other pattern names are a good quick way to explain what's going on in a stock, but they're not the reason it's tradable – instead, it all comes down to supply and demand for shares.

  That $90 resistance level is a price where there has been an excess of supply of shares; in other words, it's a place where sellers have been more eager to step in and take gains than buyers have been to buy. That's what makes a breakout above it so significant – the move means buyers are finally strong enough to absorb all of the excess supply above that price level. Don't be early on this trade.

• [By Seth Jayson]

  Margins matter. The more Ansys (Nasdaq: ANSS  ) keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders. Healthy margins often separate pretenders from the best stocks in the market. That's why we check up on margins at least once a quarter in this series. I'm looking for the absolute numbers, so I can compare them to current and potential competitors, and any trend that may tell me how strong Ansys's competitive position could be.

• [By GURUFOCUS]

  ANSYS, Inc. (ANSS), the market leader in simulation-driven product development software, declined after reporting quarterly results that were negatively impacted by slower end market demand. Despite the near-term headwind, we believe that ANSYS remains the dominant global provider of simulation software and that the company stands to benefit from the ongoing adoption of its simulation tools. We also believe that ANSYS will increasingly use its cash to repurchase its shares, which we believe will generate additional shareholder value.

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Ansys (Nasdaq: ANSS  ) , whose recent revenue and earnings are plotted below.

Top 10 Information Technology Companies To Watch In Right Now: priceline.com Incorporated(PCLN)

priceline.com Incorporated, together with its subsidiaries, operates as an online travel company. The company provides price-disclosed hotel reservation services on a worldwide basis primarily under the Booking.com, priceline.com, and Agoda brand names; and price-disclosed rental car reservation services in approximately 80 countries through TravelJigsaw brand name. It also offers its customers the ability to purchase other travel services, including retail airline tickets; rental car days; vacations packages consisting of airfare, hotel, and rental car components; cruise trips; and destination services, including parking, event tickets, ground transfers, and tours through its ?Name Your Own Price? demand-collection system in the United States. In addition, the company offers an optional travel insurance package that provides coverage for trip cancellation, trip interruption, medical expenses, and emergency evacuation, as well as for loss of baggage, property, and travel d ocuments for air, hotel, and vacation package customers; and collision damage waiver insurance for rental car customers in the United States. The company?s other brands include Lowestfare.com, rentalcars.com, Breezenet.com, MyTravelGuide.com, Travelweb, hotelroom.com, and Car Hire 3000. priceline.com Incorporated was founded in 1997 and is headquartered in Norwalk, Connecticut.

Advisors' Opinion:

• [By Chris Umiastowski]

  Almost one year ago, I added the online travel giant Priceline.com, Inc. (PCLN) to my Strategy Lab portfolio. At the time, the stock had already been a star performer in the S&P 500 (SPX) for several years, and I bought my shares at about $627 (US) each.

Top 10 Information Technology Companies To Watch In Right Now: Essex Property Trust Inc. (ESS)

Essex Property Trust, Inc. operates as a self-administered and self-managed real estate investment trust in the United States. It engages in the ownership, operation, management, acquisition, development, and redevelopment of apartment communities, as well as commercial properties. As of March 31, 2012, the company owned or had interests in 158 apartment communities; and 5 commercial buildings, as well as 5 development projects. Its communities are located in Los Angeles, Orange, Riverside, San Diego, Santa Barbara, and Ventura counties in southern California; and the San Francisco Bay area in northern California, as well as in the Seattle metropolitan area. The company has elected to be taxed as a real estate investment trust. As a result, it would not be subject to corporate income tax on that portion of its net income that is distributed to shareholders. Essex Property Trust, Inc. was founded in 1971 and is headquartered in Palo Alto, California.

Advisors' Opinion:

• [By Amanda Alix]

  With 93% of the multifamily units breaking ground in the first quarter slated for rental, apartment REITs like AvalonBay Communities (NYSE: AVB  ) , Essex Property Trust Inc. (NYSE: ESS  ) and Equity Residential (NYSE: EQR  ) are looking like a great way to invest in the new "renter nation".

Top 10 Information Technology Companies To Watch In Right Now: Provectus Pharmaceuticals Inc (PVCT)

Provectus Pharmaceuticals, Inc., incorporated on May 1, 1978, is a development-stage pharmaceutical company that is primarily engaged in developing ethical pharmaceuticals for oncology and dermatology indications. The Company develops and focuses to license or market and sells its two prescription drug candidates, PV-10 and PH-10. The Company has transferred all its intellectual property related to over the counter (OTC) products and non-core technologies to its subsidiaries and designated, such subsidiaries as non-core to its primary business of developing its oncology and dermatology prescription drug candidates. The Company focuses on developing its prescription drug candidates PV-10 and PH-10. The Company is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer, and breast cancer. The Company is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions such as psoriasis and atopic dermatitis, a type of eczema. All of the Company's prescription drug candidates are in either the pre-clinical or clinical trial stage.

PV-10

As of December 31, 2011, the Company is developing PV-10, a sterile injectible form of rose bengal disodium (Rose Bengal), for direct injection into tumors. Its PV-10 is retained in diseased or damaged tissue but dissipates from healthy tissue. The Company had conducted Phase I and Phase IIstudies of PV-10 for the treatment of metastatic melanoma, and Phase I studies of PV-10 for the treatment of liver and breast cancers.

PH-10

The Company�� prescription drug candidate PH-10 is an aqueous hydrogel formulation of Rose Bengal for topical administration to the skin. The Company is developing PH-10 for the treatment of cutaneous skin disorders, specifically psoriasis and atopic dermatitis. In August 2011, the Company completed follow-up of all Phase IIc patients.

Over-the-Counter Pharmaceuticals

The Company had desi! gnated its subsidiary that holds its OTC products, GloveAid and Pure-ific, Pure-Stick, Pure N Clear as non-core. The Company�� GloveAid is a hand cream with both antiperspirant and antibacterial properties, for the comfort of users��hands during and after the wearing of disposable gloves. Its Pure-ific line of products includes two quick-drying sprays, Pure-ific and Pure-ific Kids, that immediately kill up to 99.9% of germs on skin and prevent regrowth for six hours. Pure-ific products prevent the spread of germs and thus complement its other OTC products designed to treat irritated skin or skin conditions, such as acne, eczema, dandruff and fungal infections. Its Pure-ific sprays have been designed with convenience in mind and are targeted towards mothers, travelers, and anyone concerned about the spread of sickness-causing germs.

The Company�� acne products Pure-Stick and Pure N Clear work by decreasing the production of fats, oils and sweat that create an environment conducive to unchecked growth of bacteria. Secondly, the products also act to reduce the number bacteria already present. The Pure-Stick and Pure N Clear are applied topically to affected areas there are no safety concerns with healthy skin.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Provectus Biopharmaceuticals (NYSE: PVCT) was also down, falling 3.02 percent to $3.01, letting out some air after the company's opening on the NYSE Friday.

• [By Luke Jacobi]

  Provectus Biopharmaceuticals (NYSE: PVCT) was also down, falling 3.38 percent to $3.01, letting out some air after the company's opening on the NYSE Friday.